More than 10 percent of severe COVID-19 patients have antibodies that attack type I interferon instead of the virus, according to a study published in Science Sept. 24. (Photo courtesy of COL Kevin Chung)
Next-generation sequencing flowcells enable rapid state-of-the-art whole genome sequencing for individuals with COVID-19 in The American Genome Center at USU. (Photo by Theodore Mueller)
USU faculty members Dr. Clifton Dalgard (left) and Dr. Andrew Snow (right) are among the many USU co-authors of two Science articles published Sept. 24 detailing how genetic and immunological abnormalities in the Type I inteferon pathway are risk factors for severe COVID-19 disease. (Dalgard photo courtesy of HJF; Snow photo courtesy of Dr. Andrew Snow)